Products for Research Use Only
RegisterLogin

Tandutinib

CAT: 0804-HY-10202-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10202-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) [1][2]. Tandutinib has the ability to cross the blood-brain barrier[3].
CAS Number
387867-13-2
Product Name Alternative
MLN518; CT53518
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; c-Kit; FLT3; PDGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Tandutinib.html
Purity
99.48
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(C2=C(C(C=C3OCCCN4CCCCC4)=NC=N2)C=C3OC)CC1)NC5=CC=C(OC(C)C)C=C5
Molecular Formula
C31H42N6O4
Molecular Weight
562.70
Precautions
H302, H315, H319, H335
References & Citations
[1]Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) . Cancer Cell, 2002, 1 (5), 421-432.|[2]Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104 (9), 2912-2918.|[3]Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4 (4) :201-12.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDGFR

Alternative Products

CatalogName
FT28001Tandutinib
B2627-5EZSolution™ Tandutinib
MBS385163-01Tandutinib (MLN518)

Popular Products